SG11202108604WA - Use of a stimulating agent to assay immune cell potency - Google Patents

Use of a stimulating agent to assay immune cell potency

Info

Publication number
SG11202108604WA
SG11202108604WA SG11202108604WA SG11202108604WA SG11202108604WA SG 11202108604W A SG11202108604W A SG 11202108604WA SG 11202108604W A SG11202108604W A SG 11202108604WA SG 11202108604W A SG11202108604W A SG 11202108604WA SG 11202108604W A SG11202108604W A SG 11202108604WA
Authority
SG
Singapore
Prior art keywords
immune cell
stimulating agent
cell potency
assay immune
assay
Prior art date
Application number
SG11202108604WA
Inventor
Dean Anthony Lee
Aarohi Thakkar
Mark Hall
Jennifer Muszynski
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of SG11202108604WA publication Critical patent/SG11202108604WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11202108604WA 2019-02-14 2020-02-14 Use of a stimulating agent to assay immune cell potency SG11202108604WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805349P 2019-02-14 2019-02-14
PCT/US2020/018377 WO2020168250A1 (en) 2019-02-14 2020-02-14 Use of a stimulating agent to assay immune cell potency

Publications (1)

Publication Number Publication Date
SG11202108604WA true SG11202108604WA (en) 2021-09-29

Family

ID=72044856

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108604WA SG11202108604WA (en) 2019-02-14 2020-02-14 Use of a stimulating agent to assay immune cell potency

Country Status (13)

Country Link
US (1) US20220128564A1 (en)
EP (1) EP3924368A4 (en)
JP (1) JP2022520810A (en)
KR (1) KR20210138592A (en)
CN (1) CN113811543A (en)
AU (1) AU2020221310A1 (en)
BR (1) BR112021015750A2 (en)
CA (1) CA3129929A1 (en)
CO (1) CO2021012002A2 (en)
IL (1) IL285578A (en)
MX (1) MX2021009786A (en)
SG (1) SG11202108604WA (en)
WO (1) WO2020168250A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115478051B (en) * 2022-10-12 2023-04-18 北京奇迈永华生物科技有限公司 Method for efficiently culturing human NK cells in serum-free manner

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778750A (en) * 1986-02-19 1988-10-18 Imreg, Inc. Diagnostic methods for immune function
US5363860A (en) * 1992-10-20 1994-11-15 Nakao Naomi L Suction trap and associated method
WO1994020120A1 (en) * 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
EP1019546B1 (en) * 1996-03-26 2004-12-15 Cylex, Inc. Methods for measurement of lymphocyte function
DK1537419T3 (en) * 2002-09-13 2011-06-27 Lfb Biotechnologies Test for CD16-mediated ADCC efficacy of monoclonal and polyclonal antibodies
EP2047246A4 (en) * 2006-07-28 2009-11-04 Univ New York State Res Found Methods and kits for measurement of lymphocyte function
JP7049830B2 (en) * 2014-10-27 2022-04-07 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド Methods and compositions for natural killer cells
JP6884155B2 (en) * 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド Combination immunotherapy and cytokine control therapy for cancer treatment
SG11201811745UA (en) * 2016-06-28 2019-01-30 Geneius Biotechnology Inc T cell compositions for immunotherapy

Also Published As

Publication number Publication date
CA3129929A1 (en) 2020-08-20
WO2020168250A1 (en) 2020-08-20
MX2021009786A (en) 2021-09-08
US20220128564A1 (en) 2022-04-28
KR20210138592A (en) 2021-11-19
EP3924368A4 (en) 2022-12-14
EP3924368A1 (en) 2021-12-22
BR112021015750A2 (en) 2021-10-26
AU2020221310A1 (en) 2021-10-07
IL285578A (en) 2021-09-30
CO2021012002A2 (en) 2021-09-30
CN113811543A (en) 2021-12-17
JP2022520810A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
IL277858A (en) Antibodies specific to human nectin4
IL273414A (en) Restoration of t cell activity via the cd39/cd73 axis
HUE058347T2 (en) Use of epimerase enzymes for conversion of fructose to allulose
EP3790562A4 (en) Modification of immune cells to increase activity
PL3411473T3 (en) Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy
IL285422A (en) Transposon-based modifications of immune cells
SG11202111436TA (en) Using blockchain transactions to provide off-chain functionality
SG11202101242VA (en) A method to specifically stimulate survival and expansion of genetically-modified immune cells
EP4017842C0 (en) Preparation of urea solution and facility to do so
IL285578A (en) Use of a stimulating agent to assay immune cell potency
IL292155A (en) Stimulation of neuronal plasticity
IL284807A (en) Antibodies specific to human nectin-2
GB2595619B (en) Upper body of garment
IL275884A (en) Human antibodies to influenza hemagglutinin
PL3779447T3 (en) Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer
PL3729079T3 (en) Potency assay of secretomes
AU2019266339A1 (en) Modification of immune cells to increase activity
GB202101287D0 (en) A mixture for external application to the human body
IL307472A (en) Measurement of therapeutic proteins co-administered to a subject by lc-mrm-ms assay
IL281932A (en) Antibodies directed to filamin-a and therapeutic uses thereof
GB202114501D0 (en) Immune cell therapy
GB202015814D0 (en) Hgf-ai/app to solve covid-19
IL288922A (en) Bacteria-engineered to elicit antigen-specific t-cells
CA191314S (en) Piece of construction set [toy]
CA191312S (en) Piece of construction set [toy]